Table 2.

Summary of adverse events in the safety population of the OPTIMUS-3 Study

Adverse event	Prasugrel 60 mg LD/10 mg MD (n = 34), n (%)	Clopidogrel 600 mg LD/150 mg MD (n = 35), n (%)
Number of patients with at least one event	5 (14.7)	9 (25.7)
Number of events	8	19
Haematocrit decreaseda	1 (2.9)	0
Haemoglobin decreaseda	1 (2.9)	0
Headache	1 (2.9)	2 (5.7)
Pain in extremity	1 (2.9)	0
Upper respiratory tract infection	1 (2.9)	1 (2.9)
Urinary tract infection	1 (2.9)	0
Vessel puncture site haemorrhage	1 (2.9)	0
Contusion	0	1 (2.9)
Diarrhoea	0	1 (2.9)
Electrolyte imbalance	0	1 (2.9)
Epistaxis	0	1 (2.9)
Haemorrhage	0	1 (2.9)
Nausea	0	1 (2.9)
Respiratory tract congestion	0	1 (2.9)
Rhinorrhoea	0	1 (2.9)
Sinusitis	0	1 (2.9)
Vomiting	0	1 (2.9)
Wart excision	0	1 (2.9)

^aInvestigator defined.